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An Effective AIDS Vaccine Based on
Live Attenuated Vesicular
Stomatitis Virus Recombinants
(Hinman, 1999). Vaccination with a live virus typically
results in sustained, high-level intracellular synthesis of
viral proteins. This high-level expression stimulates
strong cellular and humoral immune responses and re-
sults in production of long-lasting memory B and T cells.
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Based on studies with attenuated simian immunodefi-1 Departments of Pathology and Cell Biology
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would probably be an effective AIDS vaccine. However,New Haven, Connecticut 06510
testing of such a vaccine has been delayed because of2 Aaron Diamond AIDS Research Center
the risk of disease associated with live attenuated HIVNew York, New York 10016
immunization.3 Tulane University Health Sciences Center
Recent emphasis in AIDS vaccine research has beenNew Orleans, Louisiana 70043
placed on protocols that stimulate strong cellular im-4 Gladstone Institute of Virology and Immunology
mune responses. This is in part because such responsesSan Francisco, California 94141
correlate well with nonprogression to AIDS in people5 Department of Surgery
infected with HIV (Musey et al., 1997; Ogg et al., 1998;Duke University Medical Center
Rosenberg et al., 1997). In addition, cellular immuneDurham, North Carolina 27710
responses are responsible for early control of viral repli-
cation before neutralizing antibodies are generated
(Borrow et al., 1994; Chen et al., 1995; Koup et al., 1994;Summary
Pantaleo et al., 1994). Cellular immune responses have
also been emphasized in HIV vaccine development be-We developed an AIDS vaccine based on attenuated
cause the single envelope glycoprotein (Env) of HIV isVSV vectors expressing env and gag genes and tested
a poor target for neutralizing antibodies, the Env se-it in rhesus monkeys. Boosting was accomplished us-
quences are highly divergent, and antibody-resistanting vectors with glycoproteins from different VSV sero-
mutants are generated and selected rapidly (Burton,types. Animals were challenged with a pathogenic
1997). Therefore, development of a vaccine that com-AIDS virus (SHIV89.6P). Control monkeys showed a
pletely protects from infection may not be a realisticsevere loss of CD4 T cells and high viral loads, and
goal. Two important recent studies indicate that it is7/8 progressed to AIDS with an average time of 148
possible to obtain a high degree of protection againstdays. All seven vaccinees were initially infected with
AIDS in a monkey model, without protecting againstSHIV89.6P but have remained healthy for up to 14
infection. This has been accomplished by inducing amonths after challenge with low or undetectable viral
strong cellular immune response by four injections ofloads. Protection from AIDS was highly significant (p
DNA expression plasmids encoding viral proteins and0.001). VSV vectors are promising candidates for hu-
a stabilized interleukin 2 (Barouch et al., 2000) or by twoman AIDS vaccine trials because they propagate to
injections of DNA plasmids followed by boosting with ahigh titers and can be delivered without injection.
third injection of an attenuated vaccinia virus recombi-
nant expressing viral proteins (Amara et al., 2001). TheseIntroduction
vaccination protocols reduced the replication of the
challenge virus, gave good preservation of CD4 T cells,
The AIDS epidemic that began more than 20 years ago
and prevented AIDS.
has killed more than 22 million people. The latest esti-
Vaccines based on a live attenuated animal virus
mate is that 36.1 million people are living with HIV infec- called vesicular stomatitis virus (VSV) have been highly
tion or AIDS (UNAIDS, 2000). Approximately 5.3 million effective in animal models and are particularly attractive
new infections occurred last year and the epidemic is because they can be administered by a mucosal route
contributing to the destruction of the economic and so- without injection (Roberts et al., 1998). For example, a
cial structure and destabilization of the political systems single intranasal vaccination with a live attenuated VSV
of several developing countries. A safe and effective recombinant expressing an influenza virus hemaggluti-
AIDS vaccine that can be prepared easily in large quanti- nin protein completely protects mice against a lethal
ties and delivered on a global scale is needed urgently challenge with influenza virus (Roberts et al., 1998,
to halt this epidemic. 1999). Another VSV recombinant expressing the mea-
Vaccines based on live viruses have traditionally been sles virus hemagglutinin induced protective immunity to
highly effective and relatively easy to produce and de- measles challenge after a single intranasal vaccination
liver. For example, the worldwide elimination of smallpox in cotton rats (Schlereth et al., 2000).
was accomplished through mass vaccination with live In nature, VSV infection causes vesicular lesions of the
vaccinia virus, a mildly pathogenic animal virus related tongue, teats, and hooves of livestock including cows,
to smallpox virus. Live attenuated poliovirus vaccine has horses, and pigs, but infection is normally cleared within
been key in nearly eliminating polio infections worldwide two weeks (Wagner and Rose, 1996). Infection of hu-
mans with VSV does occur naturally and it can cause
mild, flu-like symptoms (Fields and Hawkins, 1967; John-6 Correspondence: john.rose@yale.edu
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son et al., 1966). In an isolated rural area of Panama
where VSV infection of animals is common, 94% of the
adult humans had been infected previously with VSV
(Tesh et al., 1969). However, in most of the world, human
infection with VSV is rare making VSV an excellent candi-
date vaccine vector. In addition the VSV recombinants
used here are attenuated in mice compared with wild-
type VSV (Roberts et al., 1998). We also report here that
these vectors are nonpathogenic in rhesus monkeys.
VSV infection in animals induces strong cellular and
antibody responses to its own proteins and to additional
proteins encoded from recombinant viruses (Kim et al.,
1998; Masopust et al., 2001; Zinkernagel et al., 1978).
VSV has an 11 kb RNA genome of negative (noncoding)
sense and replicates in the cytoplasm where it has only
RNA intermediates in replication. It synthesizes five sub-
genomic mRNAs encoding five structural proteins
(Wagner and Rose, 1996). VSV recombinants can be
recovered from DNA copies and foreign genes can be
expressed at high levels from multiple sites in the ge-
nome (Haglund et al., 2000; Kretzschmar et al., 1997;
Lawson et al., 1995; Schnell et al., 1996a, 1996b). Re-
combinant VSV genomes can accommodate at least
4.5 kb of foreign RNA and these new genes can be
expressed at high levels from at least two additional
mRNAs (Haglund et al., 2000).
Initial studies in mice established that VSV/HIV recom-
binants expressing the envelope glycoprotein of an HIV
Figure 1. Pilot Study with Two Rhesus Macaques, AR88 and AR89primary isolate can elicit HIV neutralizing antibody. This
(A) Timeline of vaccination and boosting with VSV glycoprotein ex-was accomplished by boosting with a second VSV/HIV
change vectors encoding HIV 89.6 EnvG and SIV gag and challenge
recombinant in which the VSV glycoprotein (G) is with SHIV 89.6P. Challenge was with 30 MID50 SHIV 89.6P given by
changed to avoid the neutralizing antibody generated the intravenous route.
to the initial G protein (Rose et al., 2000). Other studies (B) IFN-ELISPOT assay for CTL starting with boost at month 25.
The HIV-specific CD8 T cell responses were analyzed by interferon-have established that recombinant VSVs expressing HIV
(IFN-ELISPOT assay) in both animals following the boosts at monthEnv and Gag proteins generate vigorous primary CTL
25 and month 32. Responses are reported as spot forming cellsresponses to both proteins in mice (K. Haglund, L.B.,
(SFC)/106 PBMC.
and J.R., unpublished results). Based on the favorable
results in mice, we have now tested the ability of VSV
recombinants expressing Env and Gag proteins to im- based on the same attenuated VSV recombinant used
munize rhesus monkeys against the highly pathogenic in the first vaccinations, but have the VSV G protein
SHIV 89.6P virus, and we have followed cellular and (Indiana serotype, GI) replaced with either the G protein
humoral immune responses before and after challenge. of the VSV New Jersey serotype (GNJ) or the VSV Chan-
dipura glycoprotein (GCh) (Rose et al., 2000). We con-
structed GCh and GNJ vectors expressing the SIVmac239Results
Gag protein and the 89.6 EnvG protein and used them
in two subsequent boosts at months 25 and 32 (FigurePilot Study with Two Vaccinees
Our initial pilot study involved two rhesus macaques that 1A). Within one month after each boost, both animals
developed neutralizing antibody titers to the G(Ch) andwere vaccinated and boosted according to the schedule
given in Figure 1A. Initial vaccinations at months zero G(NJ) proteins just as in the larger study described be-
low indicating that boosting was effective (data notand two were performed with a live attenuated VSV
recombinant expressing a hybrid HIV envelope protein shown). We also detected a transient neutralizing anti-
body titer (1:40) to HIV Env 89.6 in AR88 but not in AR89,(89.6) with its cytoplasmic domain replaced with the VSV
G protein cytoplasmic domain (Johnson et al., 1997). but the neutralizing antibody was not detectable at the
time of challenge, two months after the last boost.These vaccinations were given by a combination of in-
tramuscular and oral routes. Although neutralizing anti-
body responses to VSV and total antibody to Env were CD8 T Cell Responses
The HIV-specific CD8 T cell responses were analyzeddetected by ELISA after the vaccination and boost, we
did not detect HIV neutralizing antibody (data not shown). by interferon- (IFN-) ELISPOT assay (Moretto et al.,
2000) in both animals following the boosts at month 25As described in detail below for the larger study, there
were no clinical signs associated with the vaccination and month 32. Responses are reported as spot forming
cells (SFC)/106 PBMC. The inoculation with GCh vectorsof the pilot animals. The animals were then rested for
23 months during which time effective VSV boosting expressing Env and Gag proteins stimulated HIV-Env and
SIV-Gag-specific CD8 T cell responses of moderatevectors were developed. These boosting vectors are
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strength in AR88, similar to those seen in SIVmac251nef-
infected macaques (Moretto et al., 2000). The responses
peaked at about 50 days following immunization, and
declined to baseline levels by the time of the final boost
(Figure 1B). Note that the initial response to Gag is a
primary response. The final boost stimulated a rapid
expansion in virus specific effector cells, with a particu-
larly strong anti-Env response within 30 days of the
boost and a lesser increase in the SIV-Gag-specific re-
sponse. The virus-specific effector population declined
to baseline levels prior to SHIV89.6P challenge. The vi-
rus-specific CTL responses in AR89 were much weaker
following immunization, but persisted at low levels until
challenge.
SHIV Challenge and Protection in the Pilot Study
An intravenous challenge was performed with the highly
pathogenic SHIV89.6P (Reimann et al., 1996) at two
months after the last boost. Note that the Env protein
encoded by SHIV-89.6P differs from the vaccine 89.6
Env protein in sequence and neutralization determinants
(Karlsson et al., 1997, 1998; Reimann et al., 1996). Two
additional, nonvaccinated control animals were added
to the study at this point. Both vaccinees showed CD8
T cell responses after challenge, with clear Env and Gag
responses in AR88, and only Gag responses in AR89
(Figure 1B). Neither control animal made detectable anti-
Figure 2. CD4 T Cell Counts and Viral Loads following Challenge
body to Env or CTL responses to Env or Gag after chal- with Pathogenic SHIV 89.6P
lenge (data not shown). The two vaccinated macaques in the pilot study were challenged
We followed the CD4 T cell counts (Figure 2A) as with SHIV 89.6P at two months after the last boost.
well as viral loads (Figure 2B) in all four animals after (A) CD4 T cell counts after challenge in the two vaccinees and the
two controls following challenge.challenge. Both control animals showed a severe loss
(B) Viral RNA loads in the two vaccinees and the two controls follow-of CD4 cell counts at two weeks after challenge, and
ing challenge.these counts remained at or near zero until the animals
developed AIDS at days 148 and 155. The viral loads in
both controls were 108/ml at day 14 after challenge
controls challenged intravenously with SHIV 89.6P atbut then declined to 105–106/ml after the CD4 T cell
three months following the last boost and two vaccineespopulation was largely eliminated. In contrast, the two
and three controls challenged at six months followingvaccinees showed only a moderate initial drop in CD4
the last boost.T cell counts which recovered to above 600/l. The initial
We determined that all vaccinations and boosts wereviral loads in the vaccinees were 1–2 logs lower than in
successful because neutralizing titers to the three VSVthe controls, and declined to below detection (less than
glycoproteins were detected in all five vaccinees (Figure500 copies/ml) in AR88 by day 42 and to 3  103 in
3B). The responses to the first vector (GI) were generallyAR89. Initially we were able to culture challenge virus
the strongest, with reduced titers observed to the GChfrom both animals, but after the load fell to undetectable
and GNJ vectors, although there was substantial varia-in AR88, we were not able to recover virus by coculture
tion among animals. A similar pattern of reduced re-with fresh PBMC. This animal appears to have cleared
sponses to subsequent vectors was observed pre-the infection. Both vaccinees have remained healthy for
viously in mice inoculated sequentially with the sameover 14 months after challenge.
vectors (Rose et al., 2000) and is likely due to reduction
of vector replication by cytotoxic T cells.Larger Study Involving 11 Rhesus Macaques
To attempt to obtain statistical significance in our re-
sults, we performed a larger study. We also used a more Antibody to Oligomeric gp140 and HIV
Neutralizing Antibodycompressed time frame for an initial vaccination and
two boosts. Five rhesus macaques were vaccinated and The antibody responses to the 89.6 Env glycoprotein
induced by inoculation and boost were measured by anboosted sequentially with the three VSV vectors ex-
pressing HIV EnvG (89.6) and SIV Gag proteins using ELISA assay (Richardson et al., 1996; Rose et al., 2000)
detecting antibody to oligomeric 89.6 gp140 (Figure 3C).a combination of intranasal and intramuscular routes.
Vaccination and boosting were at two month intervals By day 60 after initial vaccination, four out of the five
animals had antibody detectable by ELISA. At day 90,as shown in Figure 3A. Six control macaques were vacci-
nated and boosted at the same times with VSV vectors 30 days after the first boost, all animals showed vastly
increased ELISA titers ranging from 4,000 to 12,000.expressing an influenza virus hemagglutinin protein. The
groups were then split, with three vaccinees and three The final boost at day 120 raised the ELISA titers only
Cell
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Figure 3. Timeline and Antibody Responses
in Larger Study with 11 Rhesus Macaques
(A) Timeline of vaccination, boosting, and
challenge. Five macaques were vaccinated
and boosted with VSV G protein exchange
vectors encoding HIV 89.6 EnvG, and SIV gag
according to the schedule shown. Six control
macaques received VSV vectors encoding an
influenza hemagglutinin. Animals were split
into two groups for challenge. Three vaccin-
ees and three controls were challenged at
three months after the last boost (day 210)
and two vaccinees and three controls were
challenged at six months after the last boost
(day 313). Challenge was with 30 MID50 SHIV
89.6P given by the intravenous route.
(B) Neutralizing antibody titers to the three
VSV glycoproteins in the envelope exchange
vectors. Titers in each of the five indicated
vaccinees are given as the reciprocal of the
serum dilution that completely neutralized
100 pfu of VSV with the indicated glyco-
protein.
(C) ELISA assay for total antibody to oligo-
meric HIV Env gp140. ELISA titers are indi-
cated as the reciprocal of the serum dilution
that gave an A405 of 0.2 after subtraction of
background serum values.
marginally in most animals. As in the pilot study, we vaccinees was initially a recall response to the vaccine
Env 89.6 and did not neutralize the challenge virusobserved transient neutralizing antibody to the HIV 89.6
in some but not all animals, and these were no longer (89.6P). The two envelope proteins of these viruses differ
by 12 amino acids in their ectodomains which resultspresent at the time of challenge (data not shown). The
six animals receiving the control VSV-HA vectors all de- in major differences in their neutralization profiles (Craw-
ford et al., 1999; Karlsson et al., 1997; Montefiori et al.,veloped neutralizing antibodies to the VSV glycoproteins
and to the influenza HA (data not shown). 1998).
Neutralizing antibody to HIV 89.6 was present in allThe intravenous challenges with SHIV 89.6P were per-
formed either three or six months after the last boost as animals at day 14 after challenge, peaked at day 28, and
generally declined thereafter (Figure 4C). In contrast,indicated in Figure 3A. We measured the total antibody
responses to oligomeric Env gp140 by ELISA and the neutralizing antibody to the challenge virus did not ap-
pear until day 28 but then increased until at least dayappearance of neutralizing antibody to both HIV 89.6
(Env in vaccine) and to 89.6P (Env in challenge) in all 90 (Figure 4E). The two control animals, JO38 and N318,
that showed some ELISA titer to gp140, also showedvaccinees and all controls (Figure 4). The ELISA titers
in all vaccinees showed large increases at day 28 after some neutralizing antibody to the challenge virus but
not until day 42 (Figure 4F). The neutralizing antibodychallenge, ranging between 38,000 and 90,000 in all
animals. These then declined to between 12,000 and to 89.6P appeared two weeks earlier in the vaccinees
compared with the two controls that responded (Figure48,000 by day 90 after challenge (Figure 4A). By day 28
only 2/6 control animals showed any detectable ELISA 4E). This result suggests that the mismatched 89.6 enve-
lope in the vaccine did not antagonize the response totiter to Env, and the titers in both increased by day 90
(Figure 4B). The neutralizing antibody response in the the challenge envelope. Interestingly, the neutralizing
AIDS Vaccine Based on VSV Recombinants
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Figure 4. ELISA Titers and HIV 89.6 and 89.6P Neutralizing Titers in the Major Study following Challenge
The ELISA titers to oligomeric HIV Env proteins were determined for the vaccinees and controls following challenge (two left panels) as in
Figure 3. Neutralizing antibody titers to HIV 89.6 (Env in vaccine, central panels) and to HIV 89.6 P (Env in challenge, right panels).
titer increased to an extremely high level of 39,000 in (MHC) class I allele Mamu-A*01. We measured vaccine-
elicited CTL responses specific for the immunodominantthe JO38 control at day 90 and a low level of cross
neutralization of 89.6 was seen also (Figures 4F and 4D). Mamu-A*01 restricted SIV-Gag p11C, C-M epitope (Ku-
roda et al., 1998), using peptide specific cytokine flowThis was apparently a narrowly focused response since
the ELISA titer to gp140 was not particularly high in this cytometry (Donahoe et al., 2000). The Mamu-A*01 re-
stricted SIV-Gag p11C, C-M epitope specific CD8 Tanimal (Figure 4B). This is also the only animal from
among the controls that has not yet progressed to AIDS. cell response in AK17 showed only a small signal after
boosting. However, after challenge, this response rose
rapidly to 1.2% of the CD8CD69INF- T cells andCTL Responses in the Major Study
We measured HIV-specific CD8 T cell responses in remained high. In the paired APO5 control, there was
only a transient appearance of a low-level CTL responsemost of the vaccinees and controls using the ELISPOT
assay to detect responses to both Env and Gag epitopes after challenge and this fell to zero within 60 days. In
the two other Mamu-A*01 animals (vaccinee AJ73 and(Figure 5). The vaccinees K510, I578, and I633 made
clear Env- and Gag-specific CD8 T cell responses after control AN98) we were not able to detect CTL responses
to the p11C, C-M epitope before or after challenge (notthe first boost, but no augmentation of CD8 T cell re-
sponses was evident after the second boost. After chal- shown). Because of the small number of cells available
from these animals, we were not able to repeat a com-lenge, the vaccinees previously immunized with VSV
constructs mounted rapid and vigorous virus-specific plete analysis of their responses by ELISPOT. However,
further analyses of some time points after challengeCD8 T cell responses, with the exception of animal
I578, in which there was a high background of IFN- revealed that the vaccinee AJ73 made responses of
greater than 200 SFC/106 PBMC to both Env and Gag,production in the ELISPOT assay. K510 and I633 had
very strong responses, as high as 1000 SFC/106 PBMC. while the responses from the AN98 control were at least
10-fold lower (not shown).K510 made a strong Env-specific response, but a lower
Gag response. Of the control group, some animals made
no or a very low response (G742, AP05), while others CD4 T Cell Counts, Viral Loads, and Clinical
Events after Challenge(JO38, N318, and AV72) showed moderate increases
after challenge. After intravenous challenge with SHIV89.6P, we followed
CD4 T cell counts, viral loads, and clinical events in allTwo of the five vaccinees (AK17 and AJ73) and two
of the five controls (APO5 and AN98) were reported animals. Figure 6A shows that all controls suffered a
severe drop in CD4 T cell counts to below 100/l byto be positive for the major histocompatibility complex
Cell
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Figure 5. CTL Responses Measure by ELISPOT and Cytokine Flow Cytometry
The seven upper panels show ELISPOT analyses of CTL responses to Gag (squares) and Env (diamonds) protein epitopes, and the two lower
panels show analysis by cytokine flow cytometry for the Mamu-A*01 restricted SIV-Gag p11C, C-M epitope.
day 28 after challenge. CD4 T cell counts in four of the contrast the vaccinees generally had lower viral loads
than the controls initially and these fell to undetectablecontrols remained at low levels until they developed
AIDS between days 43 and 171 after challenge. Two of (I578 and AK17) or were between 103 and 104/ml.
The clinical events noted in the control animals in-the six controls showed a partial recovery in CD4 T
cells to about 200/l but then fell to below 100/l by cluded anorexia, severe weight loss, muscle wasting,
diarrhea, severe lymphoid depletion, retroviral pneumo-day 180 and one of these later developed AIDS. In con-
trast, the vaccinees generally showed a significant drop nia, SIV giant cells in lungs, cytomegaloviral pneumonia,
and glomerulosclerosis.in CD4 T cell numbers after challenge, but recovered
and have maintained counts averaging over 400/l for
up to nine months after challenge (Figure 6B). The two Lack of Vector-Associated Pathogenesis
or Viral Sheddinganimals (I633 and AJ73) challenged at six months after
the last boost are both maintaining good CD4 T cell Although human infection with wild-type VSV is some-
times associated with mild flu-like symptoms (Fields andnumbers (400/l) equal to the average in the group chal-
lenged earlier. Thus, the vaccine protection appears to Hawkins, 1967; Johnson et al., 1966), the attenuated
VSV vectors used in the macaques did not cause anybe long lasting.
Viral RNA measurements in the controls (Figure 6C) detectable clinical symptoms. Animals were examined
daily for two weeks after vaccination. They did not didwere consistent with the CD4 T cell counts. The four
animals that progressed to AIDS most rapidly had very not exhibit fever, vesicular lesions, or inflammation of
the mouth or throat after oral vaccination. There was nohigh initial viral loads of108/ml that dropped coincident
with CD4 T cell loss, but rebounded to 106/ml before inflammation of the nose after intranasal vaccination.
Intramuscular vaccination was not associated with in-the animals progressed to AIDS. The two control animals
that maintained low CD4 T cell counts had much lower flammation or edema. Complete blood counts were nor-
mal in all animals, behavior including eating was normal,viral loads, although the one animal with an undetectable
viral load (N318) still progressed to AIDS by day 275. In and the animals gained weight. We also attempted to
AIDS Vaccine Based on VSV Recombinants
545
Figure 6. CD4 T Cell Counts and Viral Loads following Challenge with Pathogenic SHIV 89.6P
The vaccinees and controls were challenged intravenously with SHIV 89.6P at three or six months following the last boost.
(A) CD4 T cell counts after challenge in the six control animals.
(B) CD4 T cell counts after challenge in the five vaccinees.
(C) Viral RNA loads in controls.
(D) Viral RNA loads in vaccinees.
recover the vaccine virus from nasal swabs at four and control of viral loads to low or undetectable levels, and
with the preservation of CD4 T cells in the vaccinees.seven days after intranasal inoculations and this was
unsuccessful. In mice, the attenuated VSV recombinants
replicate in the lungs after intranasal inoculation (Rob- Correlation of Immune Responses with Protection
in the Vaccinees and Controlserts et al., 1999), but we have not determined the site
of replication in the monkeys. In the pilot study, animal AR88 had stronger CTL re-
sponses to Env and Gag than did AR89, and controlled
viral load more effectively than did AR89. AR88 also hadDiscussion
stronger total antibody responses including neutralizing
antibody, than did AR89. In the larger study, the vac-Statistically Significant Protection from AIDS
Combining the results of our two studies, it is clear that cinee I578, showing the best preservation of CD4 T cell
numbers and elimination of viral load to below detection,vaccination with VSV recombinants expressing Env and
Gag proteins provides highly significant protection from had the lowest initial CTL responses after challenge,
although the responses were sustained. This animal wasAIDS (p 0.001 by a two-sided Fisher exact test). Seven
of seven vaccinees have remained disease free. The two intermediate in total antibody and neutralizing antibody
production. Other vaccinees with notably high CTL ac-vaccinees in the pilot study have remained healthy for
more than 14 months after challenge, and the vaccinees tivity (I633 and K510) controlled challenge virus replica-
tion well, but also made good antibody responses. Thein the second study have remained healthy for 11
months (early challenge group) or seven months (later general correlation of both humoral and cellular immune
responses in vaccinated animals makes it impossiblechallenge group). In contrast, seven of eight control ani-
mals progressed to AIDS with an average time of 148 to conclude that one response is more important than
the other in long-term control of viral replication. How-days (Figure 7). The protection from AIDS correlated
with large differences in peak viral loads (averaging ever, the early suppression of challenge virus replication
by day 28 in all animals is presumably due to CTL activitygreater than 10-fold higher in controls versus vaccinees),
Cell
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macaques using a VSV vector encoding an influenza
hemagglutinin protein (VSV-HA) indicates that the intra-
nasal route alone is sufficient to induce strong neutraliz-
ing antibody to both VSV and influenza virus. It appears
better than oral inoculation and as effective as intranasal
combined with intramuscular vaccination (N.R., A.L.,
P.M., A.R., and J.R., unpublished results). We therefore
plan to test this single mucosal vaccination route for
protection against AIDS in macaques. An AIDS vaccine
that could be given intranasally in drop or spray form
would be much easier to deliver on a global scale than
one requiring multiple injections. It is also important to
point out that there is no guarantee that the results from
the monkey model, using a virus that is only partially
derived from HIV, will be predictive of results in humans.
Figure 7. Percent Survival of Vaccinees Compared to Controls ver-
sus Time Advantages of VSV Vectors
The vaccinee line is shown dotted after day 250 because the two A major advantage of VSV vectors is the ease with which
vaccinees from the last challenge group are currently at day 250. they can be grown. Wild-type VSV grows to high titers
The animals from the pilot study are at day 426 and those from the in many cell lines (109 pfu/ml) and the attenuated re-
early challenge in the major study are at day 283.
combinants, expressing both HIV env and HIV gag
genes, have titers reduced only about 5-fold compared
with wild-type VSV. Minimal doses have not yet beenbecause neutralizing antibody to the challenge virus
determined for vaccination of macaques. However, inonly appeared after day 28 in all five vaccinees in the
the VSV-HA mouse model, as few as ten infectious viruslarger study.
particles given intranasally induce immune responsesAmong the control animals, there were two, JO38 and
equivalent to those generated with 105 infectious parti-N318, that managed to control viral load and preserve
cles because the vector replicates (Roberts et al., 1998,significant levels of CD4 T cells after challenge. These
1999). If the results from mice apply to primates, it mightanimals also made higher and more sustained CTL re-
be possible to produce sufficient AIDS vaccine for moresponses than the other controls. They also made total
than one billion people starting from one liter of superna-anti-Env antibody by day 28, and neutralizing antibody
tant from VSV vector-infected cells.by day 42. Interestingly, the one control animal, J038,
We do not know why the VSV vectors are able tothat has not yet developed AIDS produced a phenome-
generate such strong immune responses, but it likelynally high neutralizing antibody titer to the challenge
relates to the very high level of intracellular synthesis ofvirus (1:39,000). This is a higher neutralizing titer than
antigens in infected cells. In addition, VSV itself encodeshas been observed previously to SHIV 89.6P and may
only five proteins of its own to compete in the immunecontribute to the survival of this animal. However, as
response to the HIV proteins. In direct vector compari-in the vaccinees, the early control of challenge virus
sons in mice, we find that the humoral and cellular im-replication by day 28 in JO38 and N318 correlates well
mune responses to HIV Env expressed by VSV are 6–10with peak CTL activity when neutralizing antibody is not
fold greater than those generated by vaccinia virusyet present.
expressing the same HIV Env (K. Haglund, N.R., and J.R.,
unpublished observations). Vaccinia encodes about 200Potential for a Human AIDS Vaccine Based
proteins of its own that are presumably competing foron Attenuated VSV Recombinants
a limited immune response capability. In addition, theBased on the experiments reported here, we think it is
ability to exchange the VSV envelope G proteins andlikely that VSV recombinants expressing HIV gag and
escape the neutralizing antibody response to the vectorenv genes could be an effective AIDS vaccine in humans,
allows major boosting of immune responses. Anotherespecially if the boosting system using a vector with a
major advantage of VSV vectors is that they are replica-heterologous VSV G protein were employed. Here we
tion competent and carry out limited replication andused two different boosting vectors, but the majority of
spread until they are eliminated by nonadaptive andthe boosting, at least for antibody responses, occurred
adaptive immune responses. Because the virus repli-after the first boost. Therefore, it will be important to
cates entirely in the cytoplasm from only RNA intermedi-determine if a single vaccination or single vaccination
ates, there are no concerns about persistence throughand one boost can confer equivalent protection in the
integration host DNA or damage of host DNA.macaque model
The route of vaccination is also an important issue to
address. The ease of delivery of an AIDS vaccine will Safety
With any live virus vector, vector-associated pathogene-likely be key to stemming the worldwide AIDS epidemic.
In this study we employed a combination of oral and sis is of critical concern. In young mice, wild-type VSV
given intranasally enters the brain via the olfactory bulbintramuscular, or intranasal and intramuscular routes
for vaccination and boosting. This protocol would be and can cause encephalitis (Reiss et al., 1998). However
the VSV recombinants derived from plasmid DNA arecumbersome for mass vaccination of humans because
injection would be required. However, recent testing in sufficiently attenuated that they do not cause encephali-
AIDS Vaccine Based on VSV Recombinants
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tralizing the G Chandipura protein, a recombinant VSV Indiana ex-tis in mice, although they still cause weight loss (Roberts
pressing the G(Ch) in place of the G(I) was used. Neutralizationet al., 1998). We did not detect any pathogenesis associ-
assays were performed as follows. Monkey sera were diluted withated with the attenuated vectors in the macaques, but
PBS in a volume of 50 l in serial 2-fold dilutions in 96-well plates.
direct testing in humans will be required to establish Fifty l of each virus (approximately 100 plaque forming units) in
both safety and immunogenicity. People are commonly serum-free DMEM was added to the diluted serum in each well. The
infected with wild-type VSV in some isolated rural areas 96-well plates containing sera and virus were incubated at 37C for
1 hr. Approximately 1500 BHK cells in 100 l DMEM-10% FBS wereof the tropical Americas where VSV infection of animals
then added to each well. The plates were incubated at 37C, 5%is common (Tesh et al., 1969). These people have sub-
CO2, for 2 to 3 days. Each assay was performed in duplicate. Neu-stantial antibody titers to the virus, yet VSV infection is
tralizing titers are given as the highest dilutions which correspond
not associated with serious human disease. This situa- to complete inhibition of VSV cytopathic effect. All duplicate assays
tion also suggests that the attenuated recombinants agreed within one dilution.
employed here will be nonpathogenic in humans. How-
ever, if further attenuation is required, for example in HIV Neutralizing Antibody Assays
Antibody-mediated neutralization of SHIV-89.6 and SHIV-89.6P wasimmunization of immunocompromised people, there are
assessed in MT-2 cells by using a reduction in virus-induced cellalso well characterized VSV deletion mutants that are
killing as described previously (Crawford et al., 1999). Briefly, 500completely or partially attenuated for pathogenesis in
TCID50 of virus were incubated with multiple dilutions of serum sam-young mice yet are still effective as vaccine vectors
ples in triplicate for 1 hr at 37C in 96-well flat-bottom culture plates.
(Roberts et al., 1999; Schnell et al., 1998). Cells were added and the incubation continued until most but not
all cells in virus control wells (cells  virus but no serum sample)
Experimental Procedures were involved in syncytium formation (usually 4–6 days). Cell viability
was then quantified by neutral red uptake. Neutralization titers are
Construction and Recovery of VSV Recombinants defined as the reciprocal serum dilution (before the addition of cells)
The construction of VSV glycoprotein exchange vectors encoding at which 50% of cells were protected from virus-induced killing. A
the 89.6 Env protein with the VSV G cytoplasmic domain has been
50% reduction in cell-killing corresponds to an approximate 90%
described previously. The SIV gag gene was first amplified by PCR
reduction in p27 Gag antigen synthesis in this assay (Bures et al.,
from plasmid p239SpSp5	 (Kestler et al., 1990; Regier and Desro-
2000). The assay stocks of both SHIVs were prepared in humansiers, 1990). This reagent was obtained through the AIDS Research
peripheral blood mononuclear cells.and Reference Reagent Program. The forward primer was 5	GATC
GATCCTCGAGAAGATGGGCGTGAGAAACTCCGTC with an under-
Preparation of Virus and Vaccinationslined XhoI site upstream of the initiator ATG codon. The reverse
Viruses used for inoculation of the macaques were grown for 18–20primer was 5	GATCCCCCCGGGCTAGCCTACTGGTCTCCTCCAAA
hr on BHK cells in serum-free DME medium followed by centrifuga-GAGAG with an underlined NheI cloning site. The PCR product was
tion to remove cell debris. The titers of viruses obtained in thecloned into the unique XhoI and NheI sites of the following three
absence of serum were reduced 3- to 5-fold compared to thosevectors, pVSV(GI) XN-1, pVSV(GNJ) XN-1, or pVSV(GCh) XN-1 which
obtained in the presence of serum. Virus samples were frozen atwere then used to recover each of the VSV recombinants expressing

80C and titers ranged from 2  107 to 108 pfu/ml after thawing.Gag. Methods of recovery were as described previously (Rose et
Virus for inoculation of macaques was diluted to a concentration ofal., 2000).
2  107 pfu/ml with DME if necessary. Macaques were inoculated
with a total of 1.0 ml (2  107 pfu) of each construct. IntramuscularElisa Assay for Total Antibody to Oligomeric HIV Env
injections were with 0.6 ml virus and intranasal or oral vaccinationsELISA assays were performed essentially as described previously
(Richardson et al., 1996; Rose et al., 2000). Costar 96-well ELISA of 0.4 ml were delivered with a syringe without a needle.
plates were first coated with 0.1 mg/ml of concanavalin A (ConA,
Sigma) in 20 mM Tris-HCl, 1 M NaCl, pH 8.5 for 2 hr at room tempera- ELISPOT Assay
ture. In the next step gp140 diluted in PBS was added. After the The ELISPOT assay using recombinant vaccinia viruses (rVV) was
binding of gp140 to ConA overnight at 4C, a blocking step with performed as previously described (Moretto et al., 2000). Cryopre-
PBS containing 10% calf serum (blocking solution) was carried out served PBMC were thawed and washed three times in medium plus
for 30 min. Each monkey serum sample was diluted 2-fold with 15% fetal calf serum. 2  105 PBMCs were resuspended in 200 l
blocking solution from 1:100 up to 1:102,400 and was added to the of medium plus 15% fetal calf serum and added to the wells of a
wells. Plates were incubated at room temperature for 2 hr. The microtiter plate. PBMCs were then infected, at a multiplicity of infec-
secondary antibody, horseradish peroxidase-conjugated goat anti- tion of 2, with rVV expressing HIV envelope, SIV gag, control vaccinia
human (Pierce), was added to the incubation at a final dilution of (Tk
), or phytohemagglutinin as positive control for 16 hr at 37C.
1:20,000 and the plates were incubated for 1.5 hr at room tempera- PBMCs were transferred to a microtiter plate (U-CyTech, Utrecht,
ture. The substrate used for colorimetric analysis was 2,2	-Azi- The Netherlands) coated with monoclonal antibody specific for rhe-
nobis(3-ethylbenzothiazoline-6-sulfonic acid) diammonium salt tab- sus IFN-. After a 5 hr incubation at 37C, PBMCs were removed
lets, 10 mg/tablet (Immunopure ABTS, Pierce). Following each
by washing with phosphate-buffered saline  0.05% Tween. The
incubation step, wells were washed three times with 200 l PBS–
wells were filled with an appropriate dilution of a biotinylated detec-
0.05% Tween-20. Following conjugate incubation, a single 2 PBS–
tor antibody and incubated for 1 hr at 37C. After incubation the0.05% Tween high salt wash was performed to lower background
wells were washed with phosphate-buffered saline  0.05% Tweenbinding. This wash was followed by three washes with 1 PBS-
and incubated with a goat anti-biotin antibody solution for 1 hr at0.05% Tween-20 wash solution. The volume added to the wells in
37C. The wells were then washed with phosphate-buffered saline each step was 100 l except for the blocking step, where a volume
0.05% Tween, and filled with a chromogenic substrate. After colorof 200 l/well was added. All incubations except the binding of
development, spots were visualized by light microscopy and ad-gp140 were carried out at room temperature. Optical densities were
justed to spot forming cells/106 PBMC.determined at a wavelength of 405 nm in a BioRad ELISA plate
reader. Titers were determined from graphs of the data and are
Cytokine Flow Cytometrygiven as the reciprocal of the serum dilution that gave an absorbance
Intracellular interferon- (IFN-) staining was performed as pre-of 0.2. Background values obtained from an identical dilution series
viously described (Moretto et al., 2000). Cryopreserved PBMC werewith preimmune sera were subtracted in each case.
thawed and washed three times in medium plus 15% fetal calf
serum. 5  105 PBMCs were resuspended in 200 l of medium plusVSV Neutralization Assays
15% fetal calf serum and added to the wells of a 96-well v-bottomWe used VSV Indiana or VSV New Jersey to detect antibodies neu-
tralizing the corresponding G proteins. To detect antibodies neu- microtiter plate (Nunc, Roskilde, Denmark). The PBMCs were then
Cell
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incubated with the Mamu-A*01 restricted p11C, C-M peptide (5 g/ Li, J., Sodroski, J., Lee-Parritz, D., and Letvin, N.L. (1995). T cell
receptor V beta repertoire in an acute infection of rhesus monkeysml) or no peptide (control) for 1 hr at 37C. Antibody to CD28 (1
g/ml) (Becton Dickinson, San Jose, CA, USA) was also added to with simian immunodeficiency viruses and a chimeric simian-human
immunodeficiency virus. J. Exp. Med. 182, 21–31.facilitate costimulation. Brefeldin A (10 g/ml) (Sigma, St Louis, MO,
USA) was added and cells were incubated for an additional 5 hr Crawford, J.M., Earl, P.L., Moss, B., Reimann, K.A., Wyand, M.S.,
at 37C. After stimulation, cells were washed in 0.02% EDTA in Manson, K.H., Bilska, M., Zhou, J.T., Pauza, C.D., Parren, P.W., et
phosphate-buffered saline and fixed in 4% paraformaldehyde in al. (1999). Characterization of primary isolate-like variants of simian-
phosphate-buffered saline for 5 min at 37C. Cells were then perme- human immunodeficiency virus. J. Virol. 73, 10199–10207.
abilized in FACSPerm (Becton Dickinson), and stained with mono- Daniel, M.D., Kirchhoff, F., Czajak, S.C., Sehgal, P.K., and Desro-
clonal antibodies specific for CD8, CD69 (Becton-Dickinson), CD3, siers, R.C. (1992). Protective effects of a live attenuated SIV vaccine
and intracellular IFN- (BioSource International, Camarillo, CA, USA) with a deletion in the nef. Science 258, 1938–1941.
for 30 min. After staining, cells were washed twice in 0.02% azide
Donahoe, S.M., Moretto, W.J., Samuel, R.V., Marx, P.A., Hanke, T.,in phosphate-buffered saline and resuspended in 1% paraformalde-
Connor, R.I., and Nixon, D.F. (2000). Direct measurement of CD8 Thyde in phosphate-buffered saline. FACS analysis was performed
cell responses in macaques infected with simian immunodeficiencyon a FACSCalibur flow cytometer and analyzed on using CellQuest
virus. Virology 272, 347–356.software.
Fields, B.N., and Hawkins, K. (1967). Human infection with the virus
of vesicular stomatitis during an epizootic. N. Engl. J. Med. 277,Determination of CD4 Counts and Viral Loads
989–994.CD4 and CD8 T cell numbers were evaluated by flow cytometry
with the following fluorochrome-labeled monoclonal antibodies: Haglund, K., Forman, J., Krausslich, H.G., and Rose, J.K. (2000).
anti-rhesus monkey CD3-fluorescein isothiocyanate (FITC) (clone Expression of human immunodeficiency virus type 1 Gag protein
FN18; Biosource International, Camarillo, CA), anti-human CD4-phy- precursor and envelope proteins from a vesicular stomatitis virus
coerythrin (PE) (clone OKT4; Ortho Diagnostic Systems, Raritan,NJ), recombinant: high-level production of virus-like particles containing
and anti-human CD8-peridinin chlorophyll protein (PerCP) (clone HIV envelope. Virology 268, 112–121.
Leu2a; Becton Dickinson Immunocytometry Systems [BDIS], San Hinman, A. (1999). Eradication of vaccine-preventable diseases.
Jose, CA). Antibodies were added to 50 l of whole blood collected Annu. Rev. Public Health 20, 211–229.
on EDTA and incubated for 15 min at RT, after which erythrocytes
Johnson, J.E., Schnell, M.J., Buonocore, L., and Rose, J.K. (1997).
were lysed by the addition of 450 l of fluorescence-activated cell
Specific targeting to CD4 cells of recombinant vesicular stomatitis
sorter lysis solution (BDIS).
viruses encoding human immunodeficiency virus envelope proteins.
The concentration of SHIV RNA in plasma was measured at Chiron
J. Virol. 71, 5060–5068.
Corporation (Emeryville, CA) by the branched DNA (bDNA) signal
Johnson, K.M., Vogel, J.E., and Peralta, P.H. (1966). Clinical andamplification assay (Pachl et al., 1995). The lower limit of detection
serological response to laboratory-acquired human infection by In-was 500 SHIV RNA copy equivalents per ml.
diana type vesicular stomatitis virus (VSV). Am. J. Trop. Med. Hyg.
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